Use cases · four workflows

How Wavera shows up
in your day.

Four agents. Four workflows. One shared clinical, financial, and operational data model. Each is live today — pick the one you want to see in your clinic first.

01Ambient charting

Ambient notes that pay attention so you can.

Take Luna into the exam room, or dictate between patients. She writes the note, extracts the plan, queues the orders, and suggests codes — while you stay present with the patient in front of you.

LUNA · LISTENING
PATIENT“I’ve had 4 episodes of diarrhea every day.”
MD“Let’s get a CBC and a chem panel.”
MD“We have to hold your treatment.”
VISIT NOTE · B. BAKERLIVE
INTERVAL HISTORY
Grade II diarrhea · iRAE
VITALS
BP 128/82 · HR 88 · T 99.1
ASSESSMENT
Hold immunotherapy
Order CBC + CMP
BILLING & DIAGNOSIS CODES
99214R19.7T45.1X5A
How it works
01
Listen passively
Luna streams the visit audio in real time. No wake words, no button presses. Audio is processed on-device and never stored.
02
Structure the note
Interval history, vitals, assessment, and billing are extracted into an oncology-native SOAP template — not a generic primary-care one.
03
Queue everything downstream
Orders for labs, imaging, referrals. ICD-10 and E/M codes. Patient instructions. All ready for your one-tap sign-off.
In the exam room

Ambient when you're with a patient. Dictation when you're not.

Luna supports both modes. In the room, she listens and captures the visit passively. Between patients, dictate a note in plain English and she structures it into problems, plan, and orders.

IN THE EXAM ROOM
MDHow's the mucositis since last cycle?
PtA little sore in the morning. Better than the first round.
MDAny diarrhea, fatigue, neuropathy?
PtFatigue yes. Numbness in my fingertips starting.
MDOK — we're going to dose-reduce paclitaxel by 20% and add B6.
WAVERA CAPTURES
TOXICITY
Mucositis · grade 1 · improving
Fatigue · grade 2 · new
Peripheral neuropathy · grade 1 · new
PLAN CHANGE
Paclitaxel dose reduction · −20% → 140 mg/m²
Add pyridoxine 50mg PO TID
CODES AUTO-CAPTURED
99214 · K12.30 · G62.0 · R53.83
FEATURE HIGHLIGHT

Transparent AI.
Every answer traces to its source.

Every clinical recommendation made by our agents is traceable to its source — NCCN guidelines, tumor board reports, pathology findings, imaging, or historical patient data. No hallucinations, no orphan claims. Click a citation; see the exact sentence it came from, highlighted in the original document.

📄
Integrated Tumor Board Report
NSCLC · B. Baker · 04/06/2026
CASE OVERVIEW

This is a 62-year-old male with metastatic NSCLC characterized by KEAP1 / SMARCA4 / TP53 co-mutations. He has a High Tumor Mutational Burden (TMB-H) at 19 mutations/Mb. He benefited from first-line chemo-immunotherapy but developed severe, grade 3+ immune-related pneumonitis, which is an absolute contraindication to further checkpoint inhibitor therapy.

KEY BIOMARKERS

PD-L1: Tumor Proportion Score (TPS) 0%. Molecular: NGS/Genomics confirm KEAP1, TP53 and SMARCA4 mutations. No actionable driver mutations (EGFR, ALK, ROS1) identified.

COMORBIDITIES

Endocrine: Adrenal insufficiency (managed on hydrocortisone). Hematologic: Chronic iron-deficiency anemia on iron sucrose repletion.

Luna · Clinical Summary
generated from 1 source · traceable
CURRENT STATUS

Patient has 1metastatic NSCLC with KEAP1/SMARCA4/TP53 co-mutations, PD-L1 0% 2, and TMB-high status.

CONTRAINDICATION

Further immune-checkpoint inhibitor therapy is contraindicated due to grade 3 pneumonitis 3.

COMORBIDITIES

Managed adrenal insufficiency 4 on hydrocortisone replacement.

4 citations · 0 hallucinationstraceable output
01
Ingest the document
Tumor board reports, path reports, imaging, NCCN guidelines — OCR'd, chunked, and indexed with the exact source offset preserved for every sentence.
02
Generate with receipts
Luna's summary attaches a citation to every factual claim. Each citation carries a pointer back to the exact sentence — character-for-character — it was grounded in.
03
Verify in one click
Click any citation. The document scrolls to the source sentence and highlights it. Nothing is asserted that can't be clicked through to a primary source.
02Atlas treatment manager

Build guideline-aligned regimens through natural language.

Ask in plain language. Atlas pulls from notes, tumor board summaries, imaging, and the current NCCN guideline — then proposes a regimen. Preview orders and the infusion timeline, approve, and Wavera schedules the cycles, arms lab holds, and monitors toxicity.

MD“Patient progressed — what’s the next standard treatment?”
LUNAReading 5 sources · anchoring to NCCN
SOURCES · 5
Visit Note
C34.11 · 04/20
Tumor Board
Summary · 04/18
Scan Rpt 15
Path · OCR
PET CT
Imaging · 04/15
NCCN NSCLC
v3.2026
RECOMMENDATIONNCCN · 1A
Ramucirumab + Docetaxel
2L · NSCLC · post-platinum
Source · 5 docs · confidence 0.94
REGIMEN · DAY 1 · q21dPREVIEW
AGENT
DOSE
TIMING
Ramucirumab
10 mg/kg IV
60 min
Docetaxel
75 mg/m² IV
60 min
Dexamethasone
8 mg PO
Pre-med
Ondansetron
16 mg PO
Pre-med
INFUSION TIMELINE · CYCLE 1 · q21d~2h 45m chair
0:000:301:001:302:002:45
Port
Flush · NS
Pre-med
Dex 8mg · Zofran 16mg · Benadryl
Ramu
10 mg/kg IV · 60 min
Doc
75 mg/m² IV · 60 min
Watch
15 min post-infusion
vitalsvitalsvitalsvitals
Labs: CBC & CMP 48h prior
Hold if ANC < 1500 or Plt < 100k
MD on-call: Dr. Sridhar · bleep 2294
ACTIVE PLAN · 4 CYCLES · q21dLIVE
C1
Apr 25
Chair 3
C2
May 16
Chair 2
C3
Jun 06
Chair 3
C4
Jun 27
Chair 2
DOSE · BSA 1.76Ramu 790 mg · Doc 132 mg / cycle
PRE-LABSCBC + CMP auto-ordered 48h before each cycle
NEXT SCANCT c/a/p · Jun 13 · after C3
INVENTORY4 cycles · reserved · $32,418 ordered
How it works
01
Ground the question
Atlas retrieves from all relevant chart sources in the tenant — prior notes, tumor board summaries, scanned path reports (OCR'd), imaging, the live NCCN guideline.
02
Propose the regimen
Ramucirumab + Docetaxel at guideline-aligned doses, with pre-meds, flush, observation window, and vitals-check markers on the infusion timeline.
03
Operationalize on approve
One click schedules 4 cycles, reserves drug inventory, auto-orders pre-labs 48h before each cycle, and arms ANC/platelet holds.
03Revenue cycle agent

Prior auths that write and submit themselves.

When a regimen needs a PA, the revenue agent reads the chart by section — problems, labs, imaging, prior therapy, provider — fills the payer form, and transmits it through fax and Availity in parallel. You sign off when it lands back approved.

PRIOR AUTH REQUESTOxaliplatin · FOLFOX · 85 mg/m² IV × 12Aetna · plan 47B
PATIENT CHARTB. Baker · MRN 4847
C18.9 · Adenoca. colon, metastatic
Stage IV · T3 N1 M1
CEA 47 ng/mL ↑
CBC wnl · LFTs wnl · Cr 1.1
PET/CT · 04/15 · 3 liver mets
Lesions 2-4 cm · progressing
FOLFIRI × 8 cycles · progressed 03/26
Bevacizumab × 4
Dr. A. Sridhar · Medical Oncology
NPI 1234567890 · DEA AS1234567
PRIOR AUTH · PA-47Bauto-generated
REQUEST · OXALIPLATIN 85 mg/m² IV · q14d × 12
DIAGNOSIS
LABORATORY
IMAGING
PRIOR TX
PROVIDER SIG
READY TO TRANSMIT
TRANSMITTING · PA-2026-04-28472 channels · parallel
PDF PACKET4 pp · 248 KB
FAX
Automated Fax
1-800-555-0142 · Aetna RX
API
Availity Essentials
x12 · 278 submission · secure
AETNA PAYER PORTAL · MONITORLIVE
PA-2026-04-2847ETA 4h · Aetna · plan 47B
Received by Aetna
04/24 · 14:32
Clinical review
pending
Decision pending
Approved
Auto-refill scheduled · claim primedAPPROVED ✓
How it works
01
Extract from the right sections
Luna scans each chart section separately — diagnosis codes from Problems, CEA + CBC from Labs, lesion measurements from Imaging — so extractions are auditable per source.
02
Assemble & sign the PDF
Payer-specific prior-auth PDF auto-generates and populates. Provider signature block fills with NPI and DEA. Packet is stamped READY TO TRANSMIT.
03
Transmit + monitor
Parallel transmission over automated fax and Availity x12 · 278. Status timeline streams back from the payer: Received → Review → Decision → Approved.
04Practice intelligence

Ask your entire practice a question.

Agents run in the background across every chart, claim, and inventory record in the tenant. Trial matching, margin analysis, demand forecasts, revenue leak detection — all surfaced as chat answers you can trust because the sources are linked.

PRACTICE INTELLIGENCELUNA · TENANT-WIDE
MDShow me all patients who could qualify for NCT01293810.
LUNA
NCT01293810 · infigratinib · FGFR3-altered urothelial · phase II
Complete · 8 candidates match all criteria
15s
8matches
2,847screened
0.3%hit rate
27clinics
B.K.94%
Urothelial · IV
FGFR3 S249C
S.R.91%
Urothelial · III
FGFR3 R248C
M.C.87%
Upper tract uroth.
FGFR3 Y375C
A.P.84%
Urothelial · progressed
FGFR3-TACC3
+ 4 more · view all
MDWhich regimens drove our margin this quarter?
LUNA
MARGIN · Q2 2026 · TOP 5 · vs Q1
72%
8%
Keytruda
58%
12%
Oxaliplatin
46%
2%
Rituximab
38%
4%
Docetaxel
22%
1%
Leucovorin
MDForecast pembrolizumab demand · next 90 days.
LUNA
PEMBROLIZUMAB · DEMAND · 18 WEEKS · 90-DAY FORECAST
NOW
past 6w · 18u forecast · 24u+18% vs. q1 · restock due week 3
agents running · 4 services · 27 clinic locations · 2,847 charts indexed
How it works
01
Ask in natural language
Clinical, operational, or financial questions. No SQL, no filter builder. The agent understands your practice schema.
02
Background agent runs
For heavy queries like trial matching, an agent runs for minutes across 2,847+ charts, cross-referencing genomic panels, staging, prior therapy, and performance status.
03
Answer with sources
Every patient match, margin figure, or forecast data point links back to the chart or claim it came from. Auditable, exportable, never a black box.

See these in your workflow.

30-minute walkthrough with a founder. We'll demo whichever agent maps best to the biggest tax on your day.